AP NEWS

2018 Inflammatory Skin Diseases Drug Development Pipeline Review - ResearchAndMarkets.com

June 11, 2018

DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The “Inflammatory Skin Diseases Drug Development Pipeline Review, 2018” report has been added to ResearchAndMarkets.com’s offering.

“Inflammatory Skin Diseases Drug Development Pipeline Review, 2018”provides an overview of the pipeline landscape for inflammatory skin disorders and comprehensive information on the therapeutics under development and key players involved in therapeutic development for acne vulgaris, rosacea and chronic urticaria (also known as hives). It also features dormant and discontinued products.

Scope

Which companies are the most active within each pipeline? Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? What are the most important R&D milestones and data publications to have happened in this disease area?

Key Topics Covered:

1 Table of Contents

2 Introduction

2.1 Inflammatory Skin Diseases Report Coverage

2.2 Acne Vulgaris - Overview

2.3 Rosacea - Overview

2.4 Chronic Urticaria Or Hives - Overview

3 Therapeutics Development

3.1 Acne Vulgaris

3.2 Rosacea

3.3 Chronic Urticaria Or Hives

4 Therapeutics Assessment

4.1 Acne Vulgaris

4.2 Rosacea

4.3 Chronic Urticaria Or Hives

5 Companies Involved in Therapeutics Development

5.1 Acne Vulgaris

5.2 Rosacea

5.3 Chronic Urticaria Or Hives

6 Dormant Projects

6.1 Acne Vulgaris

6.2 Rosacea

6.3 Chronic Urticaria Or Hives

7 Discontinued Products

7.1 Acne Vulgaris

7.2 Rosacea

7.3 Chronic Urticaria Or Hives

8 Product Development Milestones

8.1 Acne Vulgaris

8.2 Rosacea

8.3 Chronic Urticaria Or Hives

9 Appendix

Companies Mentioned

3SBio Inc Acne Vulgaris BioPharmX Inc Braintree Laboratories Inc Cassiopea SpA Cutanea Life Sciences Inc Daewoong Co Ltd Deltanoid Pharmaceuticals Inc ELORAC Inc Foamix Pharmaceuticals Ltd Galderma SA Helix BioMedix Inc Innovation Pharmaceuticals Inc Lee’s Pharmaceutical Holdings Ltd LEO Pharma A/S Melinta Therapeutics Inc Novabiotics Ltd Novan Inc Novartis AG Paratek Pharmaceuticals Inc Pfizer Inc Phagelux Inc Phosphagenics Ltd Photocure ASA Promius Pharma LLC Provectus Biopharmaceuticals Inc Realm Therapeutics Plc Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Sol-GelTechnologiesLtd Sun Pharmaceutical Industries Ltd Valeant Pharmaceuticals International Inc Vyome Biosciences Pvt Ltd

For more information about this report visit https://www.researchandmarkets.com/research/3r44wg/2018_inflammatory?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005968/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Dermatological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/11/2018 01:55 PM/DISC: 06/11/2018 01:55 PM

http://www.businesswire.com/news/home/20180611005968/en

AP RADIO
Update hourly